In a special free issue of Future Medicinal Chemistry, leading experts explore current and potential new treatment options for the deadly neglected tropical disease schistosomiasis. The journal is published by Future Science Group.
In this issue, experts discuss drug discovery and development advances towards addressing schistosomiasis, also known as bilharzia, a disease caused by parasitic worms. Schistosomiasis is the world's most deadly neglected tropical disease, killing an estimated 280,000 people annually in the African region alone, and is the second most common parasitic disease after malaria. Clinicians now rely solely on the drug praziquantel for treatment and control of schistosomiasis.
Future Medicinal Chemistry provides a monthly point of access to commentary and debate for the ever-expanding and diversifying medicinal chemistry field, enriched by the collaborative efforts of experts from a wide spectrum of specialist areas, including chemoinformaticians, physical chemists, molecular biologists and pharmacologists. The journal showcases milestones in pharmaceutical R&D and features expert analysis of emerging research – from the identification of targets, through to the discovery, design, synthesis and evaluation of bioactive agents.
